B. Escudier, C. Porta, M. Schmidinger, N. Rioux-leclercq, A. Bex et al., Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up???, Annals of Oncology, vol.27, issue.suppl_5, pp.58-68, 2016.
DOI : 10.1093/annonc/mdw328

URL : https://academic.oup.com/annonc/article-pdf/21/suppl_5/v137/484479/mdq206.pdf

V. Institut-de and . Sanitaire, Estimation nationale de l'incidence et de la mortalité par cancer en France entre, 1980.

M. Sorbellini, M. Kattan, M. Snyder, V. Reuter, R. Motzer et al., A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA, The Journal of Urology, vol.173, issue.1, pp.48-51, 2005.
DOI : 10.1097/01.ju.0000148261.19532.2c

K. Bensalah, L. Albiges, J. Bernhard, P. Bigot, T. Bodin et al., Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein, Progr??s en Urologie, vol.27, issue.1, pp.27-51, 2016.
DOI : 10.1016/S1166-7087(16)30702-3

B. Escudier, C. Porta, M. Schmidinger, F. Algaba, J. Patard et al., Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up??, Annals of Oncology, vol.25, issue.suppl 3, pp.49-56, 2014.
DOI : 10.1093/annonc/mdu259

URL : https://academic.oup.com/annonc/article-pdf/21/suppl_5/v137/484479/mdq206.pdf

S. Fuhrman, L. Lasky, and C. Limas, Prognostic significance of morphologic parameters in renal cell carcinoma, The American Journal of Surgical Pathology, vol.6, issue.7, pp.655-63, 1982.
DOI : 10.1097/00000478-198210000-00007

U. Capitanio, F. Becker, M. Blute, P. Mulders, J. Patard et al., Lymph Node Dissection in Renal Cell Carcinoma, European Urology, vol.60, issue.6, pp.1212-1232, 2011.
DOI : 10.1016/j.eururo.2011.09.003

A. Scherr, J. Lima, E. Sasse, C. Lima, and A. Sasse, Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis, BMC Cancer, vol.16, issue.Suppl 1, p.115, 2011.
DOI : 10.1053/j.seminoncol.2006.06.005

A. Ravaud, R. Motzer, H. Pandha, D. George, A. Pantuck et al., Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy, New England Journal of Medicine, vol.375, issue.23, pp.2246-54, 2016.
DOI : 10.1056/NEJMoa1611406

N. Haas, J. Manola, R. Uzzo, K. Flaherty, C. Wood et al., Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial, The Lancet, vol.387, issue.10032, 2016.
DOI : 10.1016/S0140-6736(16)00559-6

R. Motzer, N. Haas, and F. Donskov, Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)

. Clinicaltrials and . Gov, Adjuvant axitinib therapy of renal cell cancer in high risk patients (ATLAS). [page consultée le 24, 2017.

. Clinicaltrials and . Gov, Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer, 2017.

. Clinicaltrials and . Gov, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (S0931). [page consultée le 20, 2017.

P. Bigot, G. Pignot, J. Bernhard, and J. Patard, Th??rapies cibl??es n??o-adjuvantes dans le cancer du rein, Progr??s en Urologie, vol.26, issue.3, pp.191-197, 2016.
DOI : 10.1016/j.purol.2015.12.003

C. Coppin, F. Porzsolt, A. Awa, J. Kumpf, A. Coldman et al., Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev. 25 janv, issue.1, p.1425, 2005.
DOI : 10.1002/14651858.cd001425

D. Mcdermott, M. Regan, J. Clark, L. Flaherty, G. Weiss et al., Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.1, pp.133-174, 2005.
DOI : 10.1200/JCO.2005.03.206

L. Moore, M. Nickerson, P. Brennan, J. Toro, E. Jaeger et al., Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors, PLoS Genetics, vol.27, issue.6, p.1002312, 2011.
DOI : 10.1371/journal.pgen.1002312.s002

URL : https://doi.org/10.1371/journal.pgen.1002312

B. Escudier, J. Bellmunt, S. Négrier, E. Bajetta, B. Melichar et al., Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival, Journal of Clinical Oncology, vol.28, issue.13, pp.2144-50, 2010.
DOI : 10.1200/JCO.2009.26.7849

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.22, pp.3584-90, 2009.
DOI : 10.1200/JCO.2008.20.1293

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

B. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik et al., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1940, 2011.
DOI : 10.1016/S0140-6736(11)61613-9

C. Sternberg, I. Davis, J. Mardiak, C. Szczylik, E. Lee et al., Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-1069, 2010.
DOI : 10.1200/JCO.2009.23.9764

T. Choueiri, B. Escudier, T. Powles, N. Tannir, P. Mainwaring et al., Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.7, pp.917-944, 2016.
DOI : 10.1016/S1470-2045(16)30107-3

R. Motzer, B. Escudier, S. Oudard, T. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008.
DOI : 10.1016/S0140-6736(08)61039-9

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007.
DOI : 10.1056/NEJMoa066838

R. Motzer, B. Escudier, D. Mcdermott, S. George, H. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015.
DOI : 10.1056/NEJMoa1510665

R. Motzer, T. Hutson, L. Mccann, K. Deen, and T. Choueiri, Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib, New England Journal of Medicine, vol.370, issue.18, pp.1769-70, 2014.
DOI : 10.1056/NEJMc1400731

A. Molina, D. Feldman, M. Voss, M. Ginsberg, M. Baum et al., Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma, Cancer, vol.28, issue.18 suppl, pp.1868-76, 2012.
DOI : 10.1200/JCO.2009.26.3152

G. Mickisch, A. Garin, H. Van-poppel, L. De-prijck, and R. Sylvester, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, The Lancet, vol.358, issue.9286, pp.966-70, 2001.
DOI : 10.1016/S0140-6736(01)06103-7

R. Flanigan, S. Salmon, B. Blumenstein, S. Bearman, V. Roy et al., Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer, New England Journal of Medicine, vol.345, issue.23, pp.1655-1664, 2001.
DOI : 10.1056/NEJMoa003013

T. Tatsumi, C. Herrem, W. Olson, J. Finke, R. Bukowski et al., Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma, Cancer Res. 1 août, vol.63, issue.15, pp.4481-4490, 2003.

J. Barbastefano, J. Garcia, P. Elson, L. Wood, B. Lane et al., Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy, BJU International, vol.95, issue.9, pp.1266-1275, 2010.
DOI : 10.1111/j.1349-7006.1999.tb00829.x

D. Heng, J. Wells, B. Rini, B. Beuselinck, J. Lee et al., Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium, European Urology, vol.66, issue.4, pp.704-714, 2014.
DOI : 10.1016/j.eururo.2014.05.034

J. Jacobsen, K. Grankvist, T. Rasmuson, A. Bergh, G. Landberg et al., Expression of vascular endothelial growth factor protein in human renal cell carcinoma, BJU International, vol.49, issue.3, pp.297-302, 2004.
DOI : 10.1038/359843a0

. Clinicaltrials and . Gov, Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). [page consultée le 25, 2017.

. Clinicaltrials and . Gov, Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME). [page consultée le 25, 2017.

I. Park, J. Lee, J. Ahn, D. Lee, K. Lee et al., Active surveillance for metastatic or recurrent renal cell carcinoma, Journal of Cancer Research and Clinical Oncology, vol.27, issue.8, pp.1421-1429, 2014.
DOI : 10.1016/j.urolonc.2007.10.017

B. Rini, T. Dorff, P. Elson, C. Rodriguez, D. Shepard et al., Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial, The Lancet Oncology, vol.17, issue.9, pp.1317-1341, 2016.
DOI : 10.1016/S1470-2045(16)30196-6

L. Albiges, S. Oudard, S. Negrier, C. A. Gravis, G. Joly et al., Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma, Journal of Clinical Oncology, vol.30, issue.5, pp.482-489, 2012.
DOI : 10.1200/JCO.2011.37.2516

R. Iacovelli, D. Alesini, A. Palazzo, P. Trenta, M. Santoni et al., Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials, Cancer Treatment Reviews, vol.40, issue.2, pp.271-276, 2014.
DOI : 10.1016/j.ctrv.2013.09.003

S. Oudard, L. Geoffrois, A. Guillot, C. Chevreau, J. Deville et al., Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma???Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study, European Journal of Cancer, vol.62, pp.28-35, 1990.
DOI : 10.1016/j.ejca.2016.04.003

M. Johannsen, M. Staehler, C. Ohlmann, A. Flörcken, A. Schmittel et al., Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy, Annals of Oncology, vol.22, issue.3, pp.657-63, 2011.
DOI : 10.1093/annonc/mdq437

D. Velasco, G. Xie, W. Donskov, F. Albiges, L. Beuselinck et al., Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell??Carcinoma, Clinical Genitourinary Cancer, vol.15, issue.3, pp.403-410, 2017.
DOI : 10.1016/j.clgc.2017.01.005

H. Hammers, H. Verheul, B. Salumbides, R. Sharma, M. Rudek et al., Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study, Molecular Cancer Therapeutics, vol.9, issue.6, pp.1525-1560, 2010.
DOI : 10.1158/1535-7163.MCT-09-1106

I. Desar, S. Mulder, A. Stillebroer, D. Van-spronsen, W. Van-der-graaf et al., The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases, Acta Oncologica, vol.48, issue.6, pp.927-958, 2009.
DOI : 10.1080/02841860902974167

T. Powles, I. Kayani, K. Sharpe, L. Lim, J. Peters et al., A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer, Annals of Oncology, vol.24, issue.8, pp.2098-103, 2013.
DOI : 10.1093/annonc/mdt130

A. Griffioen, L. Mans, A. De-graaf, P. Nowak-sliwinska, C. De-hoog et al., Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients, Clinical Cancer Research, vol.18, issue.14, pp.3961-71, 2012.
DOI : 10.1158/1078-0432.CCR-12-0002

F. Collinson, W. Gregory, C. Mccabe, H. Howard, C. Lowe et al., The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer, BMC Cancer, vol.68, issue.11, p.598, 2012.
DOI : 10.1016/j.socscimed.2009.02.023

A. Hines-peralta and S. Goldberg, Review of Radiofrequency Ablation for Renal Cell Carcinoma, Clinical Cancer Research, vol.10, issue.18, pp.6328-6362, 2004.
DOI : 10.1158/1078-0432.CCR-050004

N. Soga, K. Yamakado, H. Gohara, H. Takaki, T. Hiraki et al., Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma, BJU International, vol.13, issue.6, pp.790-794, 2009.
DOI : 10.1097/01.RVI.0000126812.12853.77

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2009.08459.x/pdf

B. Welch, M. Callstrom, J. Morris, A. Kurup, G. Schmit et al., Feasibility and Oncologic Control after Percutaneous Image Guided Ablation of Metastatic Renal Cell Carcinoma, The Journal of Urology, vol.192, issue.2, pp.357-63, 2014.
DOI : 10.1016/j.juro.2014.03.006

T. Okuma, T. Matsuoka, A. Yamamoto, Y. Oyama, S. Hamamoto et al., Determinants of Local Progression After Computed Tomography-Guided Percutaneous Radiofrequency Ablation for Unresectable Lung Tumors: 9-Year Experience in a Single Institution, CardioVascular and Interventional Radiology, vol.29, issue.4, pp.787-93, 2010.
DOI : 10.2214/ajr.180.1.1800151

J. Barney and E. Churchill, Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy 1 1Read at the annual meeting of the American Association of Genito-Urinary Surgeons, Absecon, New Jersey, May 2, 1938., The Journal of Urology, vol.42, issue.3, pp.269-76, 1938.
DOI : 10.1016/S0022-5347(17)71516-9

H. Zaid, W. Parker, N. Safdar, B. Gershman, P. Erwin et al., Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis, The Journal of Urology, vol.197, issue.1, pp.44-53, 2017.
DOI : 10.1016/j.juro.2016.07.079

S. Dabestani, L. Marconi, F. Hofmann, F. Stewart, T. Lam et al., Local treatments for metastases of renal cell carcinoma: a systematic review, The Lancet Oncology, vol.15, issue.12, pp.549-61, 2014.
DOI : 10.1016/S1470-2045(14)70235-9

R. Kanzaki, M. Higashiyama, A. Fujiwara, T. Tokunaga, J. Maeda et al., Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year singleinstitution experience. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg, févr, vol.39, issue.2, pp.167-72, 2011.

J. Kavolius, D. Mastorakos, C. Pavlovich, P. Russo, M. Burt et al., Resection of metastatic renal cell carcinoma., Journal of Clinical Oncology, vol.16, issue.6, pp.2261-2267, 1998.
DOI : 10.1200/JCO.1998.16.6.2261

D. You, C. Lee, I. Jeong, C. Song, J. Lee et al., Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma, Journal of Cancer Research and Clinical Oncology, vol.2015, issue.11, pp.2331-2339, 2016.
DOI : 10.1093/jjco/hyu171

J. Karam, B. Rini, L. Varella, J. Garcia, R. Dreicer et al., Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma, The Journal of Urology, vol.185, issue.2, pp.439-483, 2011.
DOI : 10.1016/j.juro.2010.09.086

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668716/pdf

P. Wersäll, H. Blomgren, I. Lax, K. Kälkner, C. Linder et al., Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma, Radiotherapy and Oncology, vol.77, issue.1, pp.88-95, 2005.
DOI : 10.1016/j.radonc.2005.03.022

P. Wersäll, H. Blomgren, P. Pisa, I. Lax, K. Kälkner et al., Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma, Acta Oncologica, vol.58, issue.3, pp.493-500, 2006.
DOI : 10.1016/j.ijrobp.2003.09.012

E. Meyer, D. Stefan, D. Pasquier, G. Bernadou, G. Calais et al., Stereotactic radiotherapy (SRT) for oligometastatic (OM) relapse and metastatic oligoprogression (OP) in renal cell carcinoma (RCC) patients (pts): A study of the GETUG group, J Clin Oncol, vol.34, pp.16105-16105, 2016.

E. Fokas, M. Henzel, K. Hamm, G. Surber, G. Kleinert et al., Radiotherapie bei Hirnmetastasen eines Nierenzellkarzinoms: Sollte eine Ganzhirnbestrahlung zus??tzlich zur stereotaktischen Radiochirurgie durchgef??hrt werden? Analyse von 88 Patienten, Strahlentherapie und Onkologie, vol.37, issue.4, pp.210-217, 2010.
DOI : 10.1016/S0360-3016(97)00006-0

C. Chevreau, A. Ravaud, B. Escudier, E. Amela, R. Delva et al., A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases, Clinical Genitourinary Cancer, vol.12, issue.1, pp.50-54, 2014.
DOI : 10.1016/j.clgc.2013.09.008

D. Meerleer, G. Khoo, V. Escudier, B. Joniau, S. Bossi et al., Radiotherapy for renal-cell carcinoma, The Lancet Oncology, vol.15, issue.4, pp.170-177, 2014.
DOI : 10.1016/S1470-2045(13)70569-2

A. Ravaud, How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents, Annals of Oncology, vol.20, issue.Supplement 1, pp.7-12, 2009.
DOI : 10.1093/annonc/mdp073

L. Zhang, M. Bhasin, R. Schor-bardach, X. Wang, M. Collins et al., Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression, PLoS ONE, vol.16, issue.4, p.19144, 2011.
DOI : 10.1371/journal.pone.0019144.s001

N. Shinohara, K. Nonomura, T. Abe, S. Maruyama, T. Kamai et al., A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma, Cancer Science, vol.40, issue.9, pp.1695-700, 2012.
DOI : 10.1093/jjco/hyq027

M. Staehler, J. Kruse, N. Haseke, T. Stadler, A. Roosen et al., Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis, World Journal of Urology, vol.57, issue.4, pp.543-550, 2010.
DOI : 10.1097/01.sla.0000246847.02058.1b

Y. Park, J. Jung, B. Lee, S. Lee, S. Jeong et al., Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma, International Journal of Urology, vol.110, issue.2, pp.153-160, 2015.
DOI : 10.1111/j.1464-410X.2011.10905.x

. Clinicaltrials and . Gov, Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery. [page consultée le 08, 2017.

. Clinicaltrials and . Gov, A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT). [page consultée le 24, 2017.

A. Bex, T. Powles, and J. Karam, Role of targeted therapy in combination with surgery in renal cell carcinoma, International Journal of Urology, vol.35, issue.Suppl., pp.5-12, 2016.
DOI : 10.14694/EdBook_AM.2015.35.e239

M. Postow, J. Chesney, A. Pavlick, C. Robert, K. Grossmann et al., Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, New England Journal of Medicine, vol.372, issue.21, 2015.
DOI : 10.1056/NEJMoa1414428

H. Hammers, E. Plimack, J. Infante, B. Rini, D. Mcdermott et al., Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study, Journal of Clinical Oncology, vol.35, issue.34, 2017.
DOI : 10.1200/JCO.2016.72.1985